Clinical trials: Solid Tumors, completed
Tumors
A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)
The purpose of this trial is to determine the effect of food versus a fasted state on single-dose pharmacokinetics of BMS-540215, the active metabolite of Brivanib alaninate
- Trial name
- NCT00437437
- Testing
- Brivanib
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Bristol-Myers Squibb
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, T-Cell
Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors
Modern frontline therapy for patients with hematologic malignancies is based on intensive administration of multiple drugs. In patients with relapsed disease, response to the same drugs is generally poor, and dosages cannot be…
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, T-Cell, Juvenile Myelomonocytic Leukemia Lymphoblastic, T-cell Lymphoblastic Lymphoma
- Trial name
- NCT00640796
- Testing
- Haploidentical donor derived natural killer cell infusion, Chemotherapy, CliniMACS
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- St. Jude Children's Research Hospital
Solid Tumor
A Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HH-101 in Patients With Advanced Solid Tumors
The goal of this study is to evaluate the safety of HH-101 antibody, administered as monotherapy to participants with advanced solid tumors.
- Trial name
- NCT07554196
- Testing
- HH-101 (0.3 mg/kg), HH-101 (1 mg/kg ), HH-101 (3 mg/kg )
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Huahui Health
GIST
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with…
- Trial name
- NCT03465722
- Testing
- avapritinib, regorafenib
- Where
- 114 sites in United States, Australia and 16 more
- Volunteers
- 476 people
- Sponsor
- Blueprint Medicines Corporation
Solid Tumors, Breast Cancer
AT13387 in Adults With Refractory Solid Tumors
Background: The experimental drug AT13387 has been shown to have some anticancer effects against tumor cells by blocking a protein that affects other proteins inside certain cancer cells, and helps to prevent the cancer cells…
- Trial name
- NCT01246102
- Testing
- AT13387
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Tumors, Hypoxia
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
This is a phase I, multi-center, open-label, dose-escalation study of TH-302 in patients with advanced solid tumors. TH-302 is a hypoxia activated product designed to exploit the hypoxic nature of tumors.
- Trial name
- NCT00495144
- Testing
- TH-302
- Where
- 7 sites in United States
- Volunteers
- 129 people
- Sponsor
- Threshold Pharmaceuticals
Unspecified Adult Solid Tumor, Protocol Specific
Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell transplantation may allow the doctor to give…
- Trial name
- NCT00003899
- Testing
- filgrastim, cyclophosphamide, melphalan
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Osteosarcoma, Ewing Sarcoma
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
The is a phase II, single arm, open-label, multi-site trial studying the combination of cryoablation therapy and dual checkpoint inhibition with nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) given at the recommended phase 2…
- Conditions
- Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Relapsed Pediatric Solid Tumor
- Trial name
- NCT05302921
- Testing
- Cryoablation Therapy, Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Children's National Research Institute
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Acupressure for Reducing Anxiety in Patients Undergoing Chemotherapy
This clinical trial evaluates whether acupressure is helpful to reduce anxiety related to chemotherapy. Anxiety is experienced by many patients with cancer.
- Trial name
- NCT06322615
- Testing
- Acupressure Therapy, Educational Intervention, Electronic Health Record Review
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Solid Tumor
A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors
Epitinib (HMPL-813) is a selective EGFR tyrosine kinase inhibitor. Epitinib has demonstrated strong inhibitory effects on multiple tumors with overexpressed EGFR or sensitive EGFR mutations in pre-clinical setting.
- Trial name
- NCT02590952
- Testing
- Epitinib
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Hutchison Medipharma Limited
Cognitive/Functional Effects, Metastatic Cancer
Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors
RATIONALE: Memantine may be able to decrease side effects caused by whole-brain radiation therapy. It is not yet known if memantine is effective in preventing side effects caused by whole-brain radiation therapy.
- Conditions
- Cognitive/Functional Effects, Metastatic Cancer, Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00566852
- Testing
- Memantine, Whole brain radiation therapy
- Where
- 235 sites in United States, Canada
- Volunteers
- 554 people
- Sponsor
- Radiation Therapy Oncology Group
Locally Advanced Solid Tumor
Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors
This is an open-label, multicenter, Phase 1a study to evaluate the safety, tolerability, PK and preliminary efficacy of AN2025 and AN0025 in double or triple combination treatments with Atezolizumab in patients with locally…
- Trial name
- NCT04975958
- Testing
- AN2025, AN0025, Atezolizumab 1200 mg in 20 ML Injection
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Adlai Nortye Biopharma Co., Ltd.
Cancer
Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212
GSK1120212 is a reversible and highly selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity currently being developed for the treatment of malignant melanoma.
- Trial name
- NCT01387204
- Testing
- GSK1120212
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- GlaxoSmithKline
Cancer
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors
This is a dose-escalation, Phase I/II, open-label, three-part study. Part 1 is designed to determine the recommended dose and schedule for the orally administered MEK inhibitor trametinib, given together with the CDK4/6 inhibitor…
- Trial name
- NCT02065063
- Testing
- Trametinib, Palbociclib
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Neoplasms
A Safety Study of Oral ZSTK474 in Patients With Cancer
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of daily oral doses of ZSTK474, an oral phosphatidylinositol 3-kinase (PI3K) inhibitor, in subjects with advanced…
- Trial name
- NCT01280487
- Testing
- ZSTK474
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- Zenyaku Kogyo Co., Ltd.
Depression, Unspecified Adult Solid Tumor, Protocol Specific
Depression Screening in Patients Undergoing Radiation Therapy For Cancer
RATIONALE: Gathering information about depression in patients with cancer may help doctors learn more about the disease and plan the best treatment.
- Trial name
- NCT00951184
- Testing
- telephone-based intervention, screening questionnaire administration, study of socioeconomic and demographic variables
- Where
- 16 sites in United States
- Volunteers
- 463 people
- Sponsor
- Radiation Therapy Oncology Group
Advanced Solid Tumors
The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid Tumors
This study is an open-label, phase I clinical trial of SHR-7631 in patients with advanced solid tumors. The whole study is divided into three stages: dose escalation, dose expansion and efficacy expansion.
- Trial name
- NCT06381050
- Testing
- SHR-7631
- Where
- 2 sites in China
- Volunteers
- 76 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Neoplasms,, Metastatic Cancer,
Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer
The objective of this study will be to investigate the safety and tolerability of AZD6244 given monotherapy or in combination with docetaxel as 2nd line therapy in Japanese patients with Advanced Solid Malignancies or Locally…
- Conditions
- Neoplasms,, Metastatic Cancer,, Non-Small Cell Lung Cancer, Advanced Solid Malignancies
- Trial name
- NCT01605916
- Testing
- AZD6244
- Where
- 3 sites in Japan
- Volunteers
- 33 people
- Sponsor
- AstraZeneca
Neoplasms
A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin.
- Trial name
- NCT00264433
- Testing
- ADH -1 (Exherin™)
- Where
- 11 sites in United States, Canada
- Sponsor
- Adherex Technologies, Inc.
Neoplasms
A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) and maximum tolerated dose (MTD) of JNJ-70218902 in Part 1, and to determine the safety of JNJ-70218902 RP2D(s) in Part 2.
- Trial name
- NCT04397276
- Testing
- JNJ-70218902
- Where
- 7 sites in Canada, Israel and 1 more
- Volunteers
- 82 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.